Chiltern Expands North American Operations with a New Office in Illinois
Chiltern International announced that it has opened a new office in the Chicago area, specifically in Bannockburn, IL.
Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint and we are very excited about our expansion to the greater Chicago area. Our new office is well situated to support our efforts to recruit top-notch staff and be strategically near our clients.”
“We are extremely pleased by the success we have had attracting high-qualified staff to our Bannockburn office, and we welcome our new colleagues to the team,” Dr. Jim Esinhart, Sr. Executive VP, Global Scientific Services, Chiltern, stated. “Our new office supports Chiltern’s mission to deliver high quality services around the world, while demonstrating our commitment to clients’ needs.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
